Efficacy of Actinium-225 and Radium-223 for the treatment of radiopharmaceutical therapy-naive metastatic castrate-resistant prostate cancer: A systematic review and meta-analysis
Current Radiopharmaceuticals · 2026-11 · 19 (6) · 100116
DOI: 10.1016/j.craph.2026.100116 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Current Radiopharmaceuticals, 2026-11. Verfasst von Langhao Li und 3 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fuzhou University Affiliated Provincial Hospital, Fujian Provincial Health Commission, Fuzhou Science and Technology Bureau.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- Fuzhou University Affiliated Provincial Hospital
- Fujian Provincial Health Commission
- Fuzhou Science and Technology Bureau
Zitieren
APA
Li, L., Cai, D., Wei, Y., & Li, T. (2026). Efficacy of Actinium-225 and Radium-223 for the treatment of radiopharmaceutical therapy-naive metastatic castrate-resistant prostate cancer: A systematic review and meta-analysis. Current Radiopharmaceuticals, 19(6), 100116. https://doi.org/10.1016/j.craph.2026.100116
Vancouver
Li L, Cai D, Wei Y, Li T. Efficacy of Actinium-225 and Radium-223 for the treatment of radiopharmaceutical therapy-naive metastatic castrate-resistant prostate cancer: A systematic review and meta-analysis. Current Radiopharmaceuticals. 2026;19(6):100116. doi:10.1016/j.craph.2026.100116
BibTeX
@article{Li2026,
author = {Li, Langhao and Cai, Desheng and Wei, Yongbao and Li, Tao},
title = {Efficacy of Actinium-225 and Radium-223 for the treatment of radiopharmaceutical therapy-naive metastatic castrate-resistant prostate cancer: A systematic review and meta-analysis},
journal = {Current Radiopharmaceuticals},
year = {2026},
volume = {19},
number = {6},
pages = {100116},
doi = {10.1016/j.craph.2026.100116}
}
EUVIMED